{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T12:06:06Z","timestamp":1752667566417,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014996","name":"Health Commission of Zhejiang Province","doi-asserted-by":"publisher","award":["2023KY052, 2023KY546"],"award-info":[{"award-number":["2023KY052, 2023KY546"]}],"id":[{"id":"10.13039\/501100014996","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic kidney disease (CKD) is a prevalent pathological condition worldwide. Parathyroid hormone (PTH) is an important index related to bone metabolism in CKD patients and has not received enough attention. This study was performed to investigate the incidence and diagnostic rate of CKDin hospital as well as PTH testing and treatment for secondary hyperparathyroidism (SHPT) in patients with stage 3 to 5 CKD. The data of patients who visited Zhejiang Provincial People's Hospital from February 2006 to April 2022 were retrieved from the hospital database. All data were divided into three subgroups using PTH testing and SHPT treatment as major comparative indicators for analysis. The data were then analyzed for overall PTH testing, CKD incidence, and diagnostic rate. Among 5,301,391 patients, the incidence of CKD was 13.14%. The missed diagnosis rate for CKD was 65.76%. The total PTH testing rate was 1.22%, of which 15.37% of PTH testing was performed in patients with stage 3 to 5 CKD. The overall diagnosis rate of SHPT in patients with stage 3 to 5 CKD was 31.0%. The prophylactic medication rate was 7.4%, and the rate of post-diagnostic drug therapy was 22.2% in patients who underwent SHPT treatment. The high misdiagnosis rate and low PTH testing rate of CKD requires prompt attention from clinicians. SHPT treatment should be considered especially in patients with stage 3 to 5 CKD.<\/jats:p>","DOI":"10.1038\/s41598-023-43016-x","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T14:02:41Z","timestamp":1695391361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Misdiagnosis of chronic kidney disease and parathyroid hormone testing during the past 16 years"],"prefix":"10.1038","volume":"13","author":[{"given":"Haojie","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danna","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenfang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"issue":"10225","key":"43016_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","unstructured":"GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 395(10225), 709\u2013733 (2020).","journal-title":"Lancet"},{"issue":"7","key":"43016_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158765","volume":"11","author":"NR Hill","year":"2016","unstructured":"Hill, N. R. et al. Global prevalence of chronic kidney disease\u2013a systematic review and meta-analysis. PLoS ONE 11(7), e0158765 (2016).","journal-title":"PLoS ONE"},{"issue":"4","key":"43016_CR3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/jamainternmed.2022.6817","volume":"183","author":"L Wang","year":"2023","unstructured":"Wang, L. et al. Prevalence of chronic kidney disease in China: Results from the sixth China chronic disease and risk factor surveillance. JAMA Intern. Med. 183(4), 298\u2013310 (2023).","journal-title":"JAMA Intern. Med."},{"issue":"4","key":"43016_CR4","doi-asserted-by":"publisher","first-page":"e12902","DOI":"10.1111\/eci.12902","volume":"48","author":"JA Navarro-Garc\u00eda","year":"2018","unstructured":"Navarro-Garc\u00eda, J. A. et al. PTH, vitamin D, and the FGF-23-klotho axis and heart: Going beyond the confines of nephrology. Eur. J. Clin. Invest. 48(4), e12902 (2018).","journal-title":"Eur. J. Clin. Invest."},{"issue":"2","key":"43016_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/ckj\/sfy061","volume":"12","author":"PA Ure\u00f1a-Torres","year":"2018","unstructured":"Ure\u00f1a-Torres, P. A. et al. Novel insights into parathyroid hormone: Report of the parathyroid day in chronic kidney disease. Clin. Kidney J. 12(2), 269\u2013280 (2018).","journal-title":"Clin. Kidney J."},{"key":"43016_CR6","doi-asserted-by":"publisher","first-page":"9619253","DOI":"10.1155\/2018\/9619253","volume":"2018","author":"H Chen","year":"2018","unstructured":"Chen, H. et al. Parathyroid hormone fragments: New targets for the diagnosis and treatment of chronic kidney disease-mineral and bone disorder. Biomed. Res. Int. 2018, 9619253 (2018).","journal-title":"Biomed. Res. Int."},{"key":"43016_CR7","doi-asserted-by":"publisher","first-page":"1059828","DOI":"10.3389\/fendo.2022.1059828","volume":"13","author":"LX Zhang","year":"2022","unstructured":"Zhang, L. X. et al. Advances in the treatment of secondary and tertiary hyperparathyroidism. Front. Endocrinol. (Lausanne). 13, 1059828 (2022).","journal-title":"Front. Endocrinol. (Lausanne)."},{"key":"43016_CR8","doi-asserted-by":"publisher","first-page":"704970","DOI":"10.3389\/fmed.2021.704970","volume":"8","author":"M Pirklbauer","year":"2021","unstructured":"Pirklbauer, M., Bushinsky, D. A., Kotanko, P. & Schappacher-Tilp, G. Personalized prediction of short- and long-term PTH changes in maintenance hemodialysis patients. Front. Med. (Lausanne) 8, 704970 (2021).","journal-title":"Front. Med. (Lausanne)"},{"issue":"1","key":"43016_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group","year":"2017","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone\u00a0disorder (CKD-MBD). Kidney Int. Suppl. 7(1), 1\u201359 (2017).","journal-title":"Kidney Int. Suppl."},{"issue":"2","key":"43016_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3390\/metabo12020111","volume":"12","author":"A Hassan","year":"2022","unstructured":"Hassan, A. et al. Molecular mechanisms of parathyroid disorders in chronic kidney disease. Metabolites 12(2), 111 (2022).","journal-title":"Metabolites"},{"key":"43016_CR11","doi-asserted-by":"publisher","first-page":"657991","DOI":"10.3389\/fendo.2021.657991","volume":"12","author":"DA Niculescu","year":"2021","unstructured":"Niculescu, D. A. et al. Combined effects of vitamin D status, renal function and age on serum parathyroid hormone levels. Front. Endocrinol. (Lausanne) 12, 657991 (2021).","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"1","key":"43016_CR12","doi-asserted-by":"publisher","first-page":"R21","DOI":"10.1530\/ERC-19-0284","volume":"27","author":"M Almquist","year":"2020","unstructured":"Almquist, M., Isaksson, E. & Clyne, N. The treatment of renal hyperparathyroidism. Endocr. Relat. Cancer. 27(1), R21\u2013R34 (2020).","journal-title":"Endocr. Relat. Cancer."},{"issue":"3","key":"43016_CR13","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.kint.2015.12.001","volume":"89","author":"E Merle","year":"2016","unstructured":"Merle, E. et al. Low parathyroid hormone status induced by high dialysate calcium is an independent risk factor for cardiovascular death in hemodialysis patients. Kidney Int. 89(3), 666\u2013674 (2016).","journal-title":"Kidney Int."},{"key":"43016_CR14","doi-asserted-by":"publisher","first-page":"204201882095832","DOI":"10.1177\/2042018820958322","volume":"11","author":"Y Yu","year":"2020","unstructured":"Yu, Y. et al. Hemodialysis patients with low serum parathyroid hormone levels have a poorer prognosis than those with secondary hyperparathyroidism. Ther. Adv. Endocrinol. Metab. 11, 2042018820958322 (2020).","journal-title":"Ther. Adv. Endocrinol. Metab."},{"issue":"20","key":"43016_CR15","doi-asserted-by":"publisher","first-page":"12223","DOI":"10.3390\/ijms232012223","volume":"23","author":"L Hu","year":"2022","unstructured":"Hu, L. et al. Mineral bone disorders in kidney disease patients: The ever-current topic. Int. J. Mol. Sci. 23(20), 12223 (2022).","journal-title":"Int. J. Mol. Sci."},{"issue":"4S","key":"43016_CR16","first-page":"S1","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 100(4S), S1-276 (2021).","journal-title":"Kidney Int."},{"issue":"11","key":"43016_CR17","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1093\/ckj\/sfab089","volume":"14","author":"HY Wang","year":"2021","unstructured":"Wang, H. Y. et al. Influence of doctors\u2019 perception on the diagnostic status of chronic kidney disease: Results from 976 409 individuals with electronic health records in China. Clin. Kidney J. 14(11), 2428\u20132436 (2021).","journal-title":"Clin. Kidney J."},{"key":"43016_CR18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1471-2369-13-116","volume":"13","author":"X Kong","year":"2012","unstructured":"Kong, X. et al. Mineral and bone disorder in Chinese dialysis patients: A multicenter study. BMC Nephrol. 13, 116 (2012).","journal-title":"BMC Nephrol."},{"issue":"9","key":"43016_CR19","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1093\/ndt\/gft472","volume":"29","author":"B Bieber","year":"2014","unstructured":"Bieber, B. et al. Two-times weekly hemodialysis in China: frequency, associated patient and treatment characteristics and quality of life in the china dialysis outcomes and practice patterns study. Nephrol. Dial. Transplant. 29(9), 1770\u20131777 (2014).","journal-title":"Nephrol. Dial. Transplant."},{"issue":"5","key":"43016_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41574-021-00477-2","volume":"17","author":"A Arnold","year":"2021","unstructured":"Arnold, A. et al. Hormonal regulation of biomineralization. Nat. Rev. Endocrinol. 17(5), 261\u2013275 (2021).","journal-title":"Nat. Rev. Endocrinol."},{"key":"43016_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cca.2020.12.022","volume":"515","author":"E Cavalier","year":"2021","unstructured":"Cavalier, E. et al. The path to the standardization of PTH: Is this a realistic possibility? A position paper of the IFCC C-BM. Clin. Chim. Acta. 515, 44\u201351 (2021).","journal-title":"Clin. Chim. Acta."},{"key":"43016_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3389\/fmed.2020.00221","volume":"7","author":"M Daimon","year":"2020","unstructured":"Daimon, M. et al. Exacerbation of hyperparathyroidism, secondary to a reduction in kidney function, in individuals with Vitamin D deficiency. Front. Med. (Lausanne) 7, 221 (2020).","journal-title":"Front. Med. (Lausanne)"},{"issue":"4","key":"43016_CR23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/ndt\/gfab184","volume":"37","author":"M Bozic","year":"2022","unstructured":"Bozic, M. et al. Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: An analysis from the NEFRONA cohort. Nephrol. Dial Transplant. 37(4), 663\u2013672 (2022).","journal-title":"Nephrol. Dial Transplant."},{"issue":"Pt B","key":"43016_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.121148","volume":"311","author":"R Kaur","year":"2022","unstructured":"Kaur, R. & Singh, R. Mechanistic insights into CKD-MBD-related vascular calcification and its clinical implications. Life Sci. 311(Pt B), 121148 (2022).","journal-title":"Life Sci."},{"issue":"4","key":"43016_CR25","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.ekir.2020.12.036","volume":"6","author":"JB Wetmore","year":"2021","unstructured":"Wetmore, J. B., Ji, Y., Ashfaq, A., Gilbertson, D. T. & Roetker, N. S. Testing patterns for CKD-MBD abnormalities in a sample US population. Kidney Int. Rep. 6(4), 1141\u20131150 (2021).","journal-title":"Kidney Int. Rep."},{"issue":"10","key":"43016_CR26","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1093\/ckj\/sfab006","volume":"14","author":"Y Xu","year":"2021","unstructured":"Xu, Y., Evans, M., Soro, M., Barany, P. & Carrero, J. J. Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease. Clin Kidney J. 14(10), 2213\u20132220 (2021).","journal-title":"Clin Kidney J."},{"issue":"2","key":"43016_CR27","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3390\/nu15020336","volume":"15","author":"S Barbuto","year":"2023","unstructured":"Barbuto, S. et al. Real-world analysis of outcomes and economic burden in patients with chronic kidney disease with and without secondary hyperparathyroidism among a sample of the italian population. Nutrients 15(2), 336 (2023).","journal-title":"Nutrients"},{"issue":"5","key":"43016_CR28","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11914-019-00533-x","volume":"17","author":"E Bellorin-Font","year":"2019","unstructured":"Bellorin-Font, E., Vasquez-Rios, G. & Martin, K. J. Controversies in the management of secondary hyperparathyroidism in chronic kidney disease. Curr. Osteoporos. Rep. 17(5), 333\u2013342 (2019).","journal-title":"Curr. Osteoporos. Rep."},{"issue":"2","key":"43016_CR29","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ekir.2020.11.023","volume":"6","author":"GK Steinl","year":"2020","unstructured":"Steinl, G. K. & Kuo, J. H. Surgical management of secondary hyperparathyroidism. Kidney Int. Rep. 6(2), 254\u2013264 (2020).","journal-title":"Kidney Int. Rep."},{"issue":"1","key":"43016_CR30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2215\/CJN.12941213","volume":"10","author":"F Tentori","year":"2015","unstructured":"Tentori, F. et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: The DOPPS study. Clin. J. Am. Soc. Nephrol. 10(1), 98\u2013109 (2015).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"8","key":"43016_CR31","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3390\/ph15080952","volume":"15","author":"YC Hou","year":"2022","unstructured":"Hou, Y. C. et al. Role of calcimimetics in treating bone and mineral disorders related to chronic kidney disease. Pharm. (Basel) 15(8), 952 (2022).","journal-title":"Pharm. (Basel)"},{"key":"43016_CR32","doi-asserted-by":"crossref","unstructured":"Ketteler, M., Bover, J., Mazzaferro, S. ERA CKD-MBD working groups. Treatment of secondary hyperparathyroidism in non-dialysis CKD: An appraisal 2022s. Nephrol. Dial. Transplant. gfac236. (2022)","DOI":"10.1093\/ndt\/gfac236"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43016-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43016-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43016-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T12:24:14Z","timestamp":1700396654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43016-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["43016"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-43016-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2023,9,22]]},"assertion":[{"value":"28 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15838"}}